Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Wittman, M.D., Carboni, J.M., Yang, Z., Lee, F.Y., Antman, M., Attar, R., Balimane, P., Chang, C., Chen, C., Discenza, L., Frennesson, D., Gottardis, M.M., Greer, A., Hurlburt, W., Johnson, W., Langley, D.R., Li, A., Li, J., Liu, P., Mastalerz, H., Mathur, A., Menard, K., Patel, K., Sack, J., Sang, X., Saulnier, M., Smith, D., Stefanski, K., Trainor, G., Velaparthi, U., Zhang, G., Zimmermann, K., Vyas, D.M.(2009) J Med Chem 52: 7360-7363
- PubMed: 19778024 
- DOI: https://doi.org/10.1021/jm900786r
- Primary Citation of Related Structures:  
3I81 - PubMed Abstract: 
This report describes the biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development.
Organizational Affiliation: 
Bristol-Myers Squibb Co, Wallingford, Connecticut 06492, USA.